<DOC>
	<DOCNO>NCT01315990</DOCNO>
	<brief_summary>The purpose interventional study assess progression free survival ( one year ) patient treatment FOLFIRI cetuximab , combine optional dermal prophylaxis . Further Objectives : 1 . Development acneiforme follicular exanthema &gt; = grade 2 2 . Duration development acneiforme follicular exanthema &gt; = grade 2 3 . Development paronychia 4 . Development skin fissure ( hand foot ) 5 . Objective remission accord RECIST 1.1 6 . Rate secondary resection liver metastasis curative approach 7 . Assessment safety tolerability 8 . Overall survival 9 . Progression free survival</brief_summary>
	<brief_title>FOLFIRI Combination With Cetuximab First-line Treatment Metastatic Colorectal Cancer Including Regular Dermal Prophylaxis Prevent Acneiforme Follicular Exanthema</brief_title>
	<detailed_description>Subjects metastatic colorectal cancer confirm KRAS-wildtype status 1st line therapy include phase IV-study . Subject receive regimen FOLFIRI combination Cetuximab every two week study treatment phase . Treatment continue - disease progression - complete response - development status operability - uncontrollable exanthema grade 3 4 - intolerable toxicity diagnose . After study discontinuation end treatment , respectively , patient follow last patient treat 12 month complete 36-months follow phase . Tumor response evaluate ( accord RECIST 1.1 ) every 12 week end study treatment</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Exanthema</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologicallyconfirmed metastatic colorectal cancer ( primary tumor metastasis ) Confirmation KRAS wildtype status Confirmation EGFRExpression tumor Stadium IV Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Qualified application FOLFIRI + Cetuximab treatment Signed patient inform consent form Of either gender age 18 year Estimated lifespan 3 month Measurable disease accord RECIST 1.1 guideline . The evaluation max . 4 week Effective adequate contraceptive precaution man woman childbearing potential age ( double barrier method ) Leucocytes ≥ 3,0 x 10^9/L neutrophil ≥ 1,5 x 10^9/L , thrombocytes ≥ 100 x 10^9/L , haemoglobin ≥ 5,6 mmol/L Serum bilirubin ≤ 1,5 x ULN ( upper limit normal ) ALAT ASAT ≤ 2,5 x ULN ; metastasis liver , ALAT ASAT ≤ 5 x ULN Serum creatinin ≤ 1,5 x ULN If applicable prior operation min . 4 week ago , biopsy 1 week initiation treatment . Wounds operation completely cure No toxicity prior treatment KRASgene mutation Confirmation nonEGFRExpression Prior treatment EGRFreceptor inhibitor Prior chemotherapy mCRC , except ( neo ) adjuvant therapy , end min . 6 month recruitment Experimental treatment medication within 30 day recruitment Known hypersensitivity component chemotherapy , cetuximab , doxycycline , Reconval K1 Dermatop Rosacea Other chronic dermal disease development papula pustule Known lung fibrosis interstitial pneumonitis interstitial lung disease keratitis , ulcerative keratitis severe form dry eye Pregnancy breast feed Brain metastasis Clinical relevant coronary heart disease , myocardial infarction within last 12 month high risk uncontrollable arrhythmia Acute subacute ileus chronic coloninflammation chronic diarrhea Symptomatic peritoneal carcinomatosis Serious , nonhealing wound , ulcera bone fracture Uncontrollable arterial hypertension Therapeutic anticoagulation ( e.g . therapy marcumar ) Known dihydropyrimidine dehydrogenase deficiency GilbertMeulengrachtsyndrome Other malignant tumour less five year old . Exceptions include basocellular carcinoma situ cancer cervix uteri curative treat well untreated , locally confine , asymptotic `` low risk '' ( indolent ) prostata carcinoma ( Stage T ≤ T12a , PSA &lt; 15 ng/ml , GleasonScore ≤ 6 ) . Known abuse narcotic drug alcohol Any kind disorder compromise ability subject give write informed consent and/or comply study procedures Any significant concomitant disease exclude participation study Missing limit juristic contractual capability</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Phase IV Study</keyword>
	<keyword>Metastatic Colorectal Cancer ( mCRC</keyword>
	<keyword>Cetuximab ( Erbitux )</keyword>
	<keyword>first-line treatment</keyword>
	<keyword>acneiform follicular exanthema</keyword>
	<keyword>rash</keyword>
	<keyword>vitamin K1</keyword>
</DOC>